Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Status Recruiting

Clinical Trial Summary

Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done by PET-CT scan after 6 weeks. In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks. Non-responding patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of response assessment at each time-point).

Clinical Trial Description

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02824952
Study type	Interventional
Source	Shaare Zedek Medical Center
Contact	Nir Peled, MD PhD FCCP
Phone	+972 0 587040620
Email	nirp@szmc.org.il
Status	Recruiting
Phase	Phase 2
Start date	November 1, 2018
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05598528` - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Completed	`NCT03836469` - Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
Completed	`NCT01772225` - NSCLC Burden of Illness Study	N/A
Completed	`NCT01362296` - An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT01460472` - Immunotherapy With Racotumomab in Advanced Lung Cancer	Phase 3
Recruiting	`NCT03803137` - Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection	N/A
Completed	`NCT00528281` - A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase	Phase 1
Not yet recruiting	`NCT04592666` - Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer	Phase 2
Terminated	`NCT00480025` - GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT05784142` - Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)	Phase 2
Active, not recruiting	`NCT04475939` - Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer	Phase 3
Withdrawn	`NCT01938456` - Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer	Phase 1
Terminated	`NCT04069936` - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC	Phase 2
Recruiting	`NCT05565378` - A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04986670` - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer	N/A
Completed	`NCT00367679` - Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT00073008` - A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04581824` - Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Phase 2
Completed	`NCT00619424` - A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04940936` - Shared Decision Making on Radiation Dose for Lung Malignancies	N/A